You are here

Articles

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

published: 4 February 2021

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib vs bosutinib

published: 26 January 2021

COVID-19 therapy & drug interactions

published: 10 October 2020

Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating CML: what has changed over 7 years?

published: 31 August 2020

British Society for Haematology Guideline on the diagnosis and management of CML

published: 31 August 2020

Asciminib (ABL001) meets primary endpoint of Phase III (ACEMBL) study

published: 27 August 2020

Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission

published: 28 July 2020

CML management at the time of the COVID-19 pandemic in Italy.

published: 22 June 2020

COVID-19 in persons with chronic myeloid leukaemia

published: 4 June 2020

Join the COVID Symptom Study

published: 11 April 2020

iCMLf FAQ: CML, TKI treatment and COVID-19 disease-

published: 3 April 2020

Recommendation from the NCRI CML Subgroup- updated 27th March 2020

published: 23 March 2020

Public Health England - COVID-19 Guidance Document

published: 22 March 2020

CML and COVID-19 case collection by iCMLf

published: 19 March 2020

Guidance from iCMLf regarding COVID-19

published: 10 March 2020

European LeukemiaNet 2020 recommendations for treating CML

published: 4 March 2020

NCCN 2020 QUICK GUIDE - Guidelines for CML Patients

published: 28 February 2020

Update: An investigation into the use of app technology in patients with CML

published: 19 February 2020

Managing CML for treatment-free remission (TFR): A proposal - GIMEMA CML WP

published: 3 February 2020

Ruxolitinib Shows Noteworthy Responses in Patients with Atypical CML

published: 14 January 2020